Feb 26, 2023 / 10:00PM GMT
Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria
Feb 26, 2023 / 10:00PM GMT
=====================
Corporate Participants
=====================
* Anthony S. Marucci
Celldex Therapeutics, Inc. - Founder, President, CEO & Director
* Diane C. Young
Celldex Therapeutics, Inc. - Senior VP & Chief Medical Officer
* Sarah Cavanaugh
Celldex Therapeutics, Inc. - SVP of Corporate Affairs & Administration
* Tibor Keler
Celldex Therapeutics, Inc. - Founder, Chief Scientific Officer & Executive VP
=====================
Conference Call Participants
=====================
* Evan Porter Taddeo
Guggenheim Securities, LLC, Research Division - Research Analyst
* Kristen Brianne Kluska
Cantor Fitzgerald & Co., Research Division - Analyst
* Samuel Evan Slutsky
LifeSci Capital, LLC, Research Division - Senior Research Analyst
* Thomas Jonathan Smith
SVB Securities LLC, Research Division - Senior MD of Immunology and Metabolism &
Avanti Acquisition Corp
(NYSE:AVAN.WS)
$
0.0015
(0%)
Market Cap: 0
Enterprise Value: 0
PE Ratio: 16.99
PB Ratio: 1.31
GF Score: 0/100 Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria Transcript
Feb 26, 2023 / 10:00PM GMT
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot